Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Ene I, Ette"'
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 4, Pp n/a-n/a (2024)
Abstract Sepsis is a common disease with high morbidity and mortality among newborns in intensive care units world‐wide. Gram‐negative bacillary bacteria are the major source of infection in neonates. Gentamicin is the most widely used aminoglyco
Externí odkaz:
https://doaj.org/article/2e1ea255d86d4f57ae45484844f6d8e1
Publikováno v:
Children, Vol 11, Iss 8, p 898 (2024)
(1) Background: Gentamicin is known to be nephrotoxic and ototoxic. Although gentamicin dosage guidelines have been established for preterm and term neonates, reports do show attainment of recommended peak concentrations but toxic gentamicin concentr
Externí odkaz:
https://doaj.org/article/25a19d592957493bbda6213869e8bf18
Autor:
Bonifasius Siyuka Singu, Milka Ndapandula Ndeunyema, Ene I. Ette, Clarissa Hildegard Pieper, Roger Karel Verbeeck
Publikováno v:
BMC Pediatrics, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Gentamicin and amikacin are aminoglycoside antibiotics which are renally excreted and known to be nephrotoxic. Estimate of glomerular filtration rate (eGFR) per body surface area is lower in neonates than in adults and exposure to
Externí odkaz:
https://doaj.org/article/74a7b3c9037e4a0da262c39058ddabd2
Publikováno v:
Informatics in Medicine Unlocked, Vol 28, Iss , Pp 100813- (2022)
Combination therapy is becoming the cornerstone of pharmacotherapy. The choice of combination therapy is premised on pharmacodynamic drug – drug interactions (PDDIs). There is a disagreement among the existing PDDI reference models which undermines
Externí odkaz:
https://doaj.org/article/2465f6e396d6462094285a15db52cb19
Publikováno v:
The Journal of Clinical Pharmacology. 60:711-721
This investigation was undertaken to maximally extract hidden knowledge from an efavirenz-based trial data set using an item response theory-based approach to exposure-outcome analysis. The aim was to understand the influence of efavirenz exposure on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d708d1615ef0f061d61facaf4fd4b41
https://doi.org/10.1002/jcph.1570
https://doi.org/10.1002/jcph.1570
Publikováno v:
Epilepsy research. 157
To describe the use of a population pharmacokinetic (PopPK) model incorporating weight and ontogeny to identify effective clobazam (CLB) dosing for use in a clinical trial in pediatric patients with Dravet syndrome.Pharmacokinetic data were combined
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8654470ca3a765f656ec57e77ef90156
https://pubmed.ncbi.nlm.nih.gov/31563030
https://pubmed.ncbi.nlm.nih.gov/31563030
Publikováno v:
Alzheimer's & Dementia. 14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f3ff1b41186b5e9f79b68f91ce3be13
https://doi.org/10.1016/j.jalz.2018.06.695
https://doi.org/10.1016/j.jalz.2018.06.695
Publikováno v:
The Journal of Clinical Pharmacology. 56:365-374
A metabolic mechanism-based characterization of antiepileptic drug-drug interactions (DDIs) with clobazam in patients with Lennox-Gastaut syndrome (LGS) was performed using a population pharmacokinetic (PPK) approach. To characterize potential DDIs w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea099ce8ee9245b6f308da90ff525819
https://doi.org/10.1002/jcph.603
https://doi.org/10.1002/jcph.603
Publikováno v:
The Journal of Clinical Pharmacology. 56:213-222
An integrative population pharmacokinetics (PPK)-based approach was used to characterize the effect of hepatic impairment on clobazam PK and its major metabolite in systemic circulation, N-desmethylclobazam (N-CLB). At therapeutic clobazam dosages, N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab8e61b0918b0d6f25df400404446f83
https://doi.org/10.1002/jcph.586
https://doi.org/10.1002/jcph.586
Publikováno v:
The Journal of Clinical Pharmacology. 55:1229-1235
The study was undertaken to develop a pharmacokinetic-pharmacodynamic model to characterize efavirenz-induced neuropsychologic impairment, given preexistent impairment, which can be used for the optimization of efavirenz therapy via Monte Carlo simul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e26be579b8394ec93a2f8781f88f2f3
https://doi.org/10.1002/jcph.533
https://doi.org/10.1002/jcph.533